HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levy, A. P. Articles by Pogue, J. Search for Related Content PubMed PubMed Citation Articles by Levy, A. P. Articles by Pogue, J. Social Bookmarking                What's this?

The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes

¹ Technion Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
² Department of Medicine and Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
³ MedStar Research Institute, Washington D.C.

Address correspondence to Andrew P. Levy MD, PhD, Technion Faculty of Medicine, Haifa, Israel. E-mail: alevy@tx.technion.ac.il

The first 20% of the full text of this article appears below.

Several clinical trials (1) have demonstrated that vitamin E does not reduce future major cardiovascular (CV) events. However, these trials could not rule out the potential benefit for high-risk subgroups. Diabetic individuals who are homozygous for the haptoglobin 2 allele (Hp 2-2) are at high risk for CV events (2–4); moreover, the Hp 2-2 protein product is . . . [Full Text of this Article]

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Asleh, S. Blum, S. Kalet-Litman, J. Alshiek, R. Miller-Lotan, R. Asaf, W. Rock, M. Aviram, U. Milman, C. Shapira, et al. Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype Diabetes, October 1, 2008; 57(10): 2794 - 2800. [Abstract] [Full Text] [PDF]

				T. Costacou, R. E. Ferrell, and T. J. Orchard Haptoglobin Genotype: A Determinant of Cardiovascular Complication Risk in Type 1 Diabetes Diabetes, June 1, 2008; 57(6): 1702 - 1706. [Abstract] [Full Text] [PDF]

				U. Milman, S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, Y. Anbinder, J. Alshiek, L. Bennett, M. Kostenko, M. Landau, et al. Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 341 - 347. [Abstract] [Full Text] [PDF]

				S. Blum, R. Asaf, J. Guetta, R. Miller-Lotan, R. Asleh, R. Kremer, N. S. Levy, F. G. Berger, D. Aronson, X. Fu, et al. Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice J. Am. Coll. Cardiol., January 2, 2007; 49(1): 82 - 87. [Abstract] [Full Text] [PDF]

				A. P. Levy, J. E. Levy, S. Kalet-Litman, R. Miller-Lotan, N. S. Levy, R. Asaf, J. Guetta, C. Yang, K. R. Purushothaman, V. Fuster, et al. Haptoglobin Genotype Is a Determinant of Iron, Lipid Peroxidation, and Macrophage Accumulation in the Atherosclerotic Plaque Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 134 - 140. [Abstract] [Full Text] [PDF]